August 15, 2016
Oncolys BioPharma said on August 10 that it will sign a deal with the National Cancer Center (NCC) Hospital East to conduct an investigator-initiated trial on OBP-301 (telomelysin), an oncolytic, telomerase-specific adenovirus type 5. The two partners plan to evaluate...read more